Meet and network with the key influencers shaping the law, policy and proceedings of Paragraph IV litigation.

Each spring, leading pharmaceutical patent litigators for brand name and generic drug companies gather at the Paragraph IV Disputes conference to discuss, debate, and analyze the latest trends, judicial rulings and legislative developments affecting Hatch-Waxman litigation.  
 
As the industry prepares to address the fall out of global pharmaceutical patent losses of billions of dollars on the Hatch-Waxman landscape, the time for this conference has never been more relevant.

 

Get judicial insights on the complex challenges facing both brand name and generic drug manufacturers:

United States Court of Appeals for the Federal Circuit

 


Honorable Kathleen M. O’Malley
United States Circuit Judge
United States Court of Appeals for the Federal Circuit

 

United States District Court

 

Honorable Stanley R. Chesler
United States District Judge
District of New Jersey

Honorable Renee M. Bumb
United States District Judge
District of New Jersey

Honorable Tonianne J. Bongiovanni
Magistrate Judge
District of New Jersey

 

Honorable Mary Pat Thynge
Chief Magistrate Judge
District of Delaware

Honorable Christopher J. Burke
Magistrate Judge
District of Delaware

Honorable Ruben Castillo
Chief Judge
Northern District of Illinois

 

Honorable Roy Payne
Magistrate Judge
Eastern District of Texas

 

United States Patent and Trademark Office, Patent Trial and Appeal Board

 

Honorable Jacqueline Wright Bonilla
Vice Chief, Administrative Patent Judge

Honorable Michelle N. Ankenbrand
Lead Administrative Patent Judge

Honorable Rama G. Elluru
Administrative Patent Judge

 

Hear from the FTC and the FDA on the latest antitrust and regulatory developments impacting Paragraph IV litigation

 

Markus H. Meier
Assistant Director, Health Care Division,
Bureau of Competition

Grail Sipes
Deputy Center Director for Regulatory
Policy, CDER

Maryll Toufanian
Director, FDA Office of Generic Drug
Policy, CDER


NEW for 2019!

THE FEDERAL CIRCUIT:
Fireside chat with the
Hon. Kathleen M. O’Malley,
United States Circuit Judge
FTC KEYNOTE: Hear directly
from Markus Meier, Assistant
Director of the Bureau of
Competition’s Health Care Division

 

MAGISTRATE JUDGES TOWN
HALL:
Perspectives from the
Districts of NJ, Del, E.D Tex.
FDA INSIGHTS: Learn from
members of the FDA’s new
Hatch-Waxman Working Group

 

TWO JUDICIAL ROUNDTABLES:
Insights from the District Court
and PTAB
SIX BREAKOUT TRACKS:
Covering budgeting, trial
preparation, and international
concerns

Exciting New Breakout Tracks Covering Budgeting, Trial Preparation, and International Concern

  1. The Business of Pharmaceutical Patent Litigation
  2. The Practice of Pharmaceutical Patent Litigation: Part I
  3. ACI’s Hatch-Waxman Series Advisory Board on “The Three C’s” (limited 20 attendees per session)
  4. A Town Hall with the Magistrate Judges (limited to 40 attendees per session)
  5. The Practice of Pharmaceutical Patent Litigation: Part II
  6. New Developments in Market Access and Exclusivities

 

Attend the conference that the “Who’s Who” of Hatch-Waxman litigators have designated as the forum which sets the standards for Paragraph IV practice. Register now and be part of the prestigious meeting of the minds.


Event Contacts

For sponsorship opportunities please contact:
American Conference Institute
[email protected]

For media partnership opportunities please contact:
Linda Lam
Tel: 212-352-3220 ext. 5538
[email protected]

 

For questions about this year’s program/content, or information on how you can speak next year please contact:
Joseph Gallagher
Tel: 212.352.3220 ext. 5511
[email protected]


 
Download the Complete Agenda to See Why 3200+ Senior Hatch-Waxman Practitioners have Joined Us for the Past 12 Years.

Enhance your learning and networking experiences by attending the

A | Biosimilars for the Hatch-Waxman Litigators Working Group

B | Parallel Proceedings Master Class


Who you will meet

Patent attorneys and litigators (in-house & law firms) who represent:
  • Brand name pharmaceutical companies
  • Generic pharmaceutical companies
  • Biopharmaceutical companies

What Our Attendee Say:      

This is the best high-level conference on Paragraph IV disputes...
– Guy Donatiello
Senior VP, Intellectual Property
Endo Pharmaceuticals


…the smaller breakout sessions allow participants to tailor their conference experience to meet their specific needs, and exchange ideas in an intimate and dynamic environment.
– Pearl T. L. Siew
Senior VP and Head, Intellectual Property
Eagle Pharmaceuticals



Connect With Us